Clopidogrel

Research use only, not for human use.

A thienopyridine-class antiplatelet agent that works by irreversibly inhibiting P2Y12 receptor on platelets.

A thienopyridine-class antiplatelet agent that works by irreversibly inhibiting P2Y12 receptor on platelets; used to reduce the risk of heart disease and stroke in those at high risk.Thrombosis Approved(In Vivo):Clopidogrel, administered during the last three months, significantly decreases blood glucose, collagen and fibronectin expression compared to vehicle-treated diabetic mice. Clopidogrel markedly ameliorates hyperglycemia-induced renal fibrosis. The combination therapy of clopidogrel and aspirin (dual-antiplatelet therapy) has been shown to be significantly beneficial compared to aspirin monotherapy and has also shown to decrease sub-acute stent thrombosis as well as recurrent ischemic events following ACS.

——

——

——

GPCR/G Protein

P2Y Receptor

P2Y12

Cardiovascular Disease

Thrombosis

113665-84-2

321.8217

C16H16ClNO2S

>98% (HPLC)

10 mM in DMSO

COC(=O)[C@H](C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3

Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (αS)-

(-20℃)

With Ice Pack

≥ 2 years